• Sustainability
  • DE&I
  • Pandemic
  • Finance
  • Legal
  • Technology
  • Regulatory
  • Global
  • Pricing
  • Strategy
  • R&D/Clinical Trials
  • Opinion
  • Executive Roundtable
  • Sales & Marketing
  • Executive Profiles
  • Leadership
  • Market Access
  • Patient Engagement
  • Supply Chain
  • Industry Trends

Deloitte Releases 12th Annual Life Sciences Industry Accounting Guide

Article

Report provides comprehensive look at financial and accounting issues faced by life sciences industry.

On Mar. 16 Deloitte released its 12th annual Life Sciences Industry Accounting Guide. The report provides a comprehensive look at some of the complex issues that finance and accounting professionals in the life sciences industry face including R&D costs, acquisitions and divestitures, consolidation, contingencies, revenue recognition, income taxes, financial instruments, and financial statement presentation and disclosure.

Some of the main themes from this year’s edition include:

  • COVID-19-Related Accounting and Financial Reporting Considerations for Life Sciences Entities
  • IPOs and SPACs
  • Revenue Recognition
  • Structured Trade Payable Arrangement

For additional information and the full report, click here.

Related Content
Merck Reaches Deal with LaNova Medicines to Develop Novel Treatment for Programmed Cell Death Protein-1 and Vascular Endothelial Growth Factor

Merck Reaches Deal with LaNova Medicines to Develop Novel Treatment for Programmed Cell Death Protein-1 and Vascular Endothelial Growth Factor

Don Tracy, Associate Editor
November 14th 2024
Article

Under terms of the collaboration, Merck will lead the development, manufacturing, and commercialization of LM-299, an investigational bispecific antibody.

BioNTech SE Strikes Deal to Acquire Biotheus

BioNTech SE Strikes Deal to Acquire Biotheus

Don Tracy, Associate Editor
November 13th 2024
Article

As part of the acquisition, BioNTech will obtain the rights to BNT327/PM8002, a bispecific antibody that targets PD-L1-low and -negative tumors that often resist checkpoint inhibitors.

Biotech Investor Sentiment Climbing Steadily, with Growing Enthusiasm Heading into 2025

Biotech Investor Sentiment Climbing Steadily, with Growing Enthusiasm Heading into 2025

Barbara Ryan
November 8th 2024
Article

The sector's XBI is up 15% year-to-date; rate cuts, election outcome, and M&A are viewed as tailwinds.

Vaccines After COVID: Biopharma's Renewed Public Health and Commercial Push

Vaccines After COVID: Biopharma's Renewed Public Health and Commercial Push

Don Tracy, Associate Editor
November 8th 2024
Article

At the Financial Times’ Global Pharma and Biotech Summit 2024, a panel discussed the potential of mRNA technology in developing cancer vaccines amid distrust from the public.

Strategies for the Looming Pharma Patent Cliff

Strategies for the Looming Pharma Patent Cliff

Don Tracy, Associate Editor
November 7th 2024
Article

At the Financial Times’ Global Pharma and Biotech Summit 2024, a panel discussed ways to prepare for the high number of incoming patent expiries and how to protect key drugs.

Specialty Value-Based Care is Improving Health Outcomes While Reducing Heath Care Costs

Specialty Value-Based Care is Improving Health Outcomes While Reducing Heath Care Costs

Beth Houck
November 7th 2024
Article

Delivering value-based care is expected to become even more prevalent, driven by factors such as patient comfort with digital tools and advancements in contractual arrangements.